{
  "azacitidine": [
    {
      "pmid": "40650712",
      "citation": "Carlos Jim\u00e9nez-Vicente et al. Enasidenib as treatment for AML with IDH2 mutation: multicenter real-life study of the early-access program in Spain.. Annals of hematology (2025 Jul)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40650712/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": 18,
      "patients_with_ae": null,
      "supporting_quotes": [
        "4%), including one grade 3 DS and one death related to this latter adverse event (AE), similar to previous findings"
      ],
      "data_source_location": "PMC Full Text",
      "extraction_confidence": 0.30000000000000004
    },
    {
      "pmid": "40498375",
      "citation": "Kyriaki Katsiki et al. Comparative Analysis of the TCR Repertoire in Bone Marrow CD8. European journal of immunology (2025 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40498375/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "PMC Full Text",
      "extraction_confidence": 0.1
    },
    {
      "pmid": "40337877",
      "citation": "Meng Chen et al. Rare cases of atraumatic splenic rupture managed conservatively in patients with myeloid neoplasms: a report of two cases and literature review.. Chinese clinical oncology (2025 Apr)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40337877/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Abstract",
      "extraction_confidence": 0.1
    },
    {
      "pmid": "40252309",
      "citation": "Julie S Braish et al. Safety and efficacy of the combination of azacitidine with venetoclax after hypomethylating agent failure in higher-risk myelodysplastic syndrome.. Leukemia research (2025 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40252309/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [
        "This Phase I/II study evaluates the safety, tolerability, and efficacy of venetoclax, an orally bioavailable BCL-2 inhibitor, in combination with azacitidine in this population"
      ],
      "data_source_location": "Abstract",
      "extraction_confidence": 0.2
    },
    {
      "pmid": "40164584",
      "citation": "Alex Bataller et al. Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study.. Blood cancer journal (2025 Mar)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40164584/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": 73,
      "patients_with_ae": null,
      "supporting_quotes": [
        "Patients in the DEC-C-Ven cohort had a more profound neutropenia at days 15 and 21 of the first cycle"
      ],
      "data_source_location": "PMC Full Text",
      "extraction_confidence": 0.30000000000000004
    },
    {
      "pmid": "40013211",
      "citation": "Marwa Mir et al. Pleural Effusion in a Patient With Chronic Myelomonocytic Leukemia Treated With Azacitidine.. Cureus (2025 Jan)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40013211/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "PMC Full Text",
      "extraction_confidence": 0.1
    },
    {
      "pmid": "39903257",
      "citation": "Kishan A Bhatt et al. Diagnosis and management of concurrent metastatic melanoma and chronic myelomonocytic leukemia.. Melanoma research (2025 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/39903257/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Abstract",
      "extraction_confidence": 0.1
    },
    {
      "pmid": "39759649",
      "citation": "Eren Arslan Davulcu et al. A Case of Chronic Myelomonocytic Leukemia With Recurrent Skin Involvement.. Cureus (2024 Dec)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/39759649/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "PMC Full Text",
      "extraction_confidence": 0.1
    },
    {
      "pmid": "39477459",
      "citation": "Robert McGrath et al. Chronic myelomonocytic leukaemia causing orbital inflammation.. BMJ case reports (2024 Oct)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/39477459/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Abstract",
      "extraction_confidence": 0.1
    },
    {
      "pmid": "39024804",
      "citation": "Kaiyue Wang et al. Targeting DNA methyltransferases for cancer therapy.. Bioorganic chemistry (2024 Oct)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/39024804/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Abstract",
      "extraction_confidence": 0.1
    },
    {
      "pmid": "38939343",
      "citation": "Krzysztof M\u0105dry et al. No advantage of antimicrobial prophylaxis in AML/MDS/CMML patients treated with azacitidine-a prospective multicenter study by the Polish Adult Leukemia Group.. Frontiers in oncology (2024)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38939343/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [
        "Azacitidine Infection Risk Model (AIR), based on red blood cell (RBC) transfusion dependency, neutropenia <0"
      ],
      "data_source_location": "PMC Full Text",
      "extraction_confidence": 0.2
    },
    {
      "pmid": "38879530",
      "citation": "Theodora Chatzilygeroudi et al. Fetal hemoglobin induction in azacytidine responders enlightens methylation patterns related to blast clearance in higher-risk MDS and CMML.. Clinical epigenetics (2024 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38879530/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "PMC Full Text",
      "extraction_confidence": 0.1
    },
    {
      "pmid": "38711181",
      "citation": "Mar Garc\u00eda-Garc\u00eda et al. Granulomatous dermatitis in the context of chronic myelomonocytic leukemia: More than just reactive infiltrates. An illustrative case report with literature review.. Journal of cutaneous pathology (2024 Aug)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38711181/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Abstract",
      "extraction_confidence": 0.1
    },
    {
      "pmid": "38595873",
      "citation": "Ghadir M Nasreddine et al. Chronic Myelomonocytic Leukemia-Associated Immune Thrombocytopenic Purpura: A Report of a Rare Case and a Review of Literature.. Cureus (2024 Mar)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38595873/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [
        "Initial treatment with subcutaneous azacytidine for CMML proved partially effective, highlighting persistent severe thrombocytopenia"
      ],
      "data_source_location": "PMC Full Text",
      "extraction_confidence": 0.2
    },
    {
      "pmid": "38387931",
      "citation": "Xiao Li et al. [Clinical Efficacy of Hypomethylating Agent Therapy in Patients with Chronic Myelomonocytic Leukemia].. Zhongguo shi yan xue ye xue za zhi (2024 Feb)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38387931/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [
        "To observe the clinical efficacy and safety of hypomethylating agent therapy in chronic myelomonocytic leukemia (CMML)"
      ],
      "data_source_location": "Abstract",
      "extraction_confidence": 0.2
    },
    {
      "pmid": "38176221",
      "citation": "Almuth Maria Anni Merz et al. Phase to phase: Navigating drug combinations with hypomethylating agents in higher-risk MDS trials for optimal outcomes.. Cancer treatment reviews (2024 Feb)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38176221/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [
        "Differences in advancements between AML and MDS treatments and hematological toxicity in HR MDS underline the importance of detailed trial designs",
        "Effective therapeutic strategies require accurate reporting of adverse events, highlighting the need for clarity in criteria like the Common Terminology Criteria for Adverse Events (CTCAE)"
      ],
      "data_source_location": "Abstract",
      "extraction_confidence": 0.2
    },
    {
      "pmid": "38091231",
      "citation": "Kensuke Usuki et al. Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11).. International journal of hematology (2024 Feb)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38091231/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": 6568,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "PMC Full Text",
      "extraction_confidence": 0.2
    },
    {
      "pmid": "38003211",
      "citation": "Maria Teresa Bochicchio et al. Germline . International journal of molecular sciences (2023 Nov)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38003211/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [
        "Chronic myelomonocytic leukemia (CMML) is a hematological neoplasm characterized by monocytosis, splenomegaly, thrombocytopenia, and anemia"
      ],
      "data_source_location": "PMC Full Text",
      "extraction_confidence": 0.2
    },
    {
      "pmid": "37994196",
      "citation": "Andrew M Brunner et al. Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes.. American journal of hematology (2024 Feb)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37994196/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [
        "The safety and efficacy of sabatolimab, a novel immunotherapy targeting T-cell immunoglobulin domain and mucin domain-3 (TIM-3), was assessed in combination with hypomethylating agents (HMAs) in patients with HMA-naive revised International Prognostic System Score (IPSS-R) high- or very high-risk myelodysplastic syndromes (HR/vHR-MDS) or chronic myelomonocytic leukemia (CMML)",
        "Sabatolimab + HMA had a safety profile similar to that reported for HMA alone and demonstrated durable clinical responses in patients with HR/vHR-MDS"
      ],
      "data_source_location": "Abstract",
      "extraction_confidence": 0.2
    },
    {
      "pmid": "37550202",
      "citation": "J Liu et al. [Effect and safety of 10-day decitabine-containing conditioning regimen for allogeneic hematopoietic stem cell transplantation in 31 patients with acute myeloid leukemia/myelodysplastic syndrome].. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi (2023 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37550202/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null
    },
    {
      "pmid": "37548390",
      "citation": "Lisa Pleyer et al. Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine-A prospective cohort study by the AGMT.. American journal of hematology (2023 Nov)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37548390/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": 1441,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Abstract",
      "extraction_confidence": 0.2
    },
    {
      "pmid": "37546162",
      "citation": "Anwarul Islam et al. An unusual response to 5-azacitidine by a patient with chronic myelomonocytic leukemia.. Clinical case reports (2023 Aug)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37546162/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "PMC Full Text",
      "extraction_confidence": 0.1
    },
    {
      "pmid": "37422688",
      "citation": "Nicholas J Short et al. A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents.. Journal of hematology & oncology (2023 Jul)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37422688/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "PMC Full Text",
      "extraction_confidence": 0.1
    },
    {
      "pmid": "37414632",
      "citation": "Vincent Jachiet et al. [Dysimmune manifestations associated with myelodysplastic neoplasms and chronic myelomonocytic leukaemias].. Bulletin du cancer (2023 Nov)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37414632/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Abstract",
      "extraction_confidence": 0.1
    },
    {
      "pmid": "37383892",
      "citation": "Lai-Jun Deng et al. Co-existing squamous cell carcinoma and chronic myelomonocytic leukemia with . World journal of clinical cases (2023 May)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37383892/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "PMC Full Text",
      "extraction_confidence": 0.1
    },
    {
      "pmid": "37083373",
      "citation": "Amer M Zeidan et al. STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453)\u00a0+\u00a0azacitidine in higher risk MDS and CMML-2.. Future oncology (London, England) (2023 Mar)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37083373/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Abstract",
      "extraction_confidence": 0.1
    },
    {
      "pmid": "37042080",
      "citation": "Raoul Tibes et al. Phase 1/1b study of azacitidine and hedgehog pathway inhibitor sonidegib in patients with myeloid neoplasms.. Cancer (2023 Aug)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37042080/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Abstract",
      "extraction_confidence": 0.1
    },
    {
      "pmid": "36845813",
      "citation": "Shekhar Gurung et al. Chronic myelomonocytic leukemia in a 72-year-old male from Nepal: A case report.. Annals of medicine and surgery (2012) (2023 Feb)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36845813/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "PMC Full Text",
      "extraction_confidence": 0.1
    },
    {
      "pmid": "36801588",
      "citation": "Tugcan Alp Kirkizlar et al. Incidence and predisposing factors of infection in patients treated with hypomethylating agents.. Leukemia research (2023 Apr)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36801588/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Abstract",
      "extraction_confidence": 0.1
    },
    {
      "pmid": "36517990",
      "citation": "Sarit Assouline et al. A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612.. Leukemia & lymphoma (2023 Feb)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36517990/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null
    },
    {
      "pmid": "36506761",
      "citation": "Jorgena Kosti et al. Extramedullary Myeloid Leukemia in the Setting of a Myeloproliferative Neoplasm.. Journal of medical cases (2022 Nov)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36506761/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "PMC Full Text",
      "extraction_confidence": 0.1
    },
    {
      "pmid": "36455187",
      "citation": "Raphael Itzykson et al. Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023 Apr)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36455187/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Abstract",
      "extraction_confidence": 0.1
    },
    {
      "pmid": "36282401",
      "citation": "Julia Reiser et al. Treatment options and survival in real life during the past three decades in patients with chronic myelomonocytic leukemia.. Wiener medizinische Wochenschrift (1946) (2023 Feb)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36282401/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "PMC Full Text",
      "extraction_confidence": 0.1
    },
    {
      "pmid": "36153475",
      "citation": "Tamara K Moyo et al. The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated\u00a0active myeloid target compound combinations in MDS/MPN overlap syndromes.. BMC cancer (2022 Sep)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36153475/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "PMC Full Text",
      "extraction_confidence": 0.1
    },
    {
      "pmid": "36150563",
      "citation": "Faezeh Darbaniyan et al. Transcriptomic Signatures of Hypomethylating Agent Failure in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia.. Experimental hematology (2022 Nov)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36150563/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Abstract",
      "extraction_confidence": 0.1
    },
    {
      "pmid": "36104395",
      "citation": "Arsene Mekinian et al. A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML.. Leukemia (2022 Nov)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36104395/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null
    },
    {
      "pmid": "36059252",
      "citation": "Yue Wei et al. MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia.. Leukemia & lymphoma (2022 Dec)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36059252/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "PMC Full Text",
      "extraction_confidence": 0.1
    },
    {
      "pmid": "35852697",
      "citation": "Takeshi Hagino et al. Myeloid leukemoid reaction after initial azacitidine therapy for chronic myelomonocytic leukemia.. International journal of hematology (2022 Dec)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/35852697/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "PMC Full Text",
      "extraction_confidence": 0.1
    },
    {
      "pmid": "35834039",
      "citation": "Yu Xu et al. Real-world data on efficacy and safety of azacitidine therapy in chronic myelomonocytic leukemia in China: results from a multicenter, retrospective study.. Investigational new drugs (2022 Oct)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/35834039/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": 24,
      "patients_with_ae": null,
      "supporting_quotes": [
        "The most common (&gt;\u200910%) AEs were thrombocytopenia (n\u2009=\u20097, 29",
        "This study provides valuable real-life data in China on the treatment schedules, efficacy and safety of AZA in the treatment of CMML"
      ],
      "data_source_location": "PMC Full Text",
      "extraction_confidence": 0.30000000000000004
    },
    {
      "pmid": "35707788",
      "citation": "Xinhui Zheng et al. Efficacy and Safety of Hypomethylating Agents in Chronic Myelomonocytic Leukemia: A Single-Arm Meta-analysis.. Global medical genetics (2022 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/35707788/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null
    },
    {
      "pmid": "35615323",
      "citation": "Antonio Cristiano et al. The Venetoclax/Azacitidine Combination Targets the Disease Clone in Acute Myeloid Leukemia, Being Effective and Safe in a Patient with COVID-19.. Mediterranean journal of hematology and infectious diseases (2022)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/35615323/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "PMC Full Text",
      "extraction_confidence": 0.1
    },
    {
      "pmid": "35488900",
      "citation": "Mikkael A Sekeres et al. A phase 1b study of glasdegib\u2009+\u2009azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes.. Annals of hematology (2022 Aug)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/35488900/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": 72,
      "patients_with_ae": null,
      "supporting_quotes": [
        "Of 72 patients enrolled, 12 were in a lead-in safety cohort (LIC) and 60 were in the AML and MDS (including CMML) expansion cohorts",
        "In the LIC, the safety profile of glasdegib\u2009+\u2009azacitidine was determined to be consistent with those of glasdegib or azacitidine alone, with no evidence of drug-drug interaction",
        "In the expansion cohort, the most frequently (\u2265\u200910%) reported non-hematologic Grade\u2009\u2265\u20093 treatment-emergent adverse events were decreased appetite, electrocardiogram QT prolongation, and hypertension in the AML cohort and sepsis, diarrhea, hypotension, pneumonia, and hyperglycemia in the MDS cohort",
        "Glasdegib\u2009+\u2009azacitidine in patients with newly diagnosed AML or MDS demonstrated an acceptable safety profile and preliminary evidence of clinical benefits"
      ],
      "data_source_location": "PMC Full Text",
      "extraction_confidence": 0.30000000000000004
    },
    {
      "pmid": "35438802",
      "citation": "Lionel Ad\u00e8s et al. A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's \"pick a winner\" trial, with the impact of somatic mutations.. British journal of haematology (2022 Aug)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/35438802/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": 322,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Abstract",
      "extraction_confidence": 0.2
    },
    {
      "pmid": "35405632",
      "citation": "A Triguero et al. Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria.. Leukemia research (2022 May)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/35405632/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Abstract",
      "extraction_confidence": 0.1
    },
    {
      "pmid": "34985762",
      "citation": "Mrinal M Patnaik et al. Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management.. American journal of hematology (2022 Mar)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34985762/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Abstract",
      "extraction_confidence": 0.1
    },
    {
      "pmid": "34966690",
      "citation": "Konstantinos Liapis et al. Approaching First-Line Treatment in Patients With Advanced CMML: Hypomethylating Agents or Cytotoxic Treatment?. Frontiers in oncology (2021)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34966690/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "PMC Full Text",
      "extraction_confidence": 0.1
    },
    {
      "pmid": "34884286",
      "citation": "Marion Delplanque et al. USAID Associated with Myeloid Neoplasm and VEXAS Syndrome: Two Differential Diagnoses of Suspected Adult Onset Still's Disease in Elderly Patients.. Journal of clinical medicine (2021 Nov)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34884286/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "PMC Full Text",
      "extraction_confidence": 0.1
    },
    {
      "pmid": "34789825",
      "citation": "Mikkael A Sekeres et al. Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML.. Leukemia (2021 Dec)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34789825/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null
    },
    {
      "pmid": "34384334",
      "citation": "Krzysztof M\u0105dry et al. Low serum albumin level deteriorates prognosis in azacitidine-treated myelodysplastic syndromes patients - results of the PALG study 'PolAZA'.. Hematology (Amsterdam, Netherlands) (2021 Dec)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34384334/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Abstract",
      "extraction_confidence": 0.1
    },
    {
      "pmid": "34268023",
      "citation": "Jay Pescatore et al. Reactivation of Pulmonary Tuberculosis During Treatment of Chronic Myelomonocytic Leukemia.. Cureus (2021 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34268023/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "PMC Full Text",
      "extraction_confidence": 0.1
    }
  ]
}